Literature DB >> 26968616

Optimizing operational efficiencies in early phase trials: The Pediatric Trials Network experience.

Amanda England1, Kelly Wade2, P Brian Smith3, Katherine Berezny4, Matthew Laughon5.   

Abstract

Performing drug trials in pediatrics is challenging. In support of the Best Pharmaceuticals for Children Act, the Eunice Kennedy Shriver National Institute of Child Health and Human Development funded the formation of the Pediatric Trials Network (PTN) in 2010. Since its inception, the PTN has developed strategies to increase both efficiency and safety of pediatric drug trials. Through use of innovative techniques such as sparse and scavenged blood sampling as well as opportunistic study design, participation in trials has grown. The PTN has also strived to improve consistency of adverse event reporting in neonatal drug trials through the development of a standardized adverse event table. We review how the PTN is optimizing operational efficiencies in pediatric drug trials to increase the safety of drugs in children.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse events; Organizational improvements; Pediatric drug trials

Mesh:

Year:  2016        PMID: 26968616      PMCID: PMC4997801          DOI: 10.1016/j.cct.2016.03.002

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.261


  51 in total

Review 1.  Interventions for non-oliguric hyperkalaemia in preterm neonates.

Authors:  Prakash Vemgal; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Hypernatremia.

Authors:  David A Goff; Valeria Higinio
Journal:  Pediatr Rev       Date:  2009-10

3.  Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation.

Authors:  Kevin M Watt; Daniel K Benjamin; Ira M Cheifetz; Ganesh Moorthy; Kelly C Wade; P Brian Smith; Kim L R Brouwer; Edmund V Capparelli; Michael Cohen-Wolkowiez
Journal:  Pediatr Infect Dis J       Date:  2012-10       Impact factor: 2.129

4.  Serial acid-base determinations in normal premature and full-term infants during the first 72 hours of life.

Authors:  A F Malan; A Evans; H D Heese
Journal:  Arch Dis Child       Date:  1965-12       Impact factor: 3.791

Review 5.  Postnatal glucose homeostasis in late-preterm and term infants.

Authors:  David H Adamkin
Journal:  Pediatrics       Date:  2011-02-28       Impact factor: 7.124

6.  Elevation in plasma creatinine and renal failure in premature neonates without major anomalies: terminology, occurrence and factors associated with increased risk.

Authors:  M W Walker; R H Clark; A R Spitzer
Journal:  J Perinatol       Date:  2010-07-22       Impact factor: 2.521

7.  Pediatric reference ranges for creatine kinase, CKMB, Troponin I, iron, and cortisol.

Authors:  S J Soldin; J N Murthy; P K Agarwalla; O Ojeifo; J Chea
Journal:  Clin Biochem       Date:  1999-02       Impact factor: 3.281

8.  Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants.

Authors:  Kelly C Wade; Daniel K Benjamin; David A Kaufman; Robert M Ward; Phillip B Smith; Bhuvana Jayaraman; Peter C Adamson; Marc R Gastonguay; Jeffrey S Barrett
Journal:  Pediatr Infect Dis J       Date:  2009-08       Impact factor: 2.129

Review 9.  Understanding clinical literature relevant to spontaneous intestinal perforations.

Authors:  Phillip V Gordon; Joshua T Attridge
Journal:  Am J Perinatol       Date:  2008-12-09       Impact factor: 1.862

10.  Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants.

Authors:  Michael Cohen-Wolkowiez; Daniele Ouellet; P Brian Smith; Laura P James; Ashley Ross; Janice E Sullivan; Michele C Walsh; Arlene Zadell; Nancy Newman; Nicole R White; Angela D M Kashuba; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

View more
  15 in total

1.  Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.

Authors:  Céline Thibault; Jean Lavigne; Catherine Litalien; Nastya Kassir; Yves Théorêt; Julie Autmizguine
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 2.  Collaboration in Regulatory Science to Facilitate Therapeutic Development for Neonates.

Authors:  Susan K McCune; Yeruk Ager Mulugeta; Gerri R Baer
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

3.  IDeA States Pediatric Clinical Trials Network for Underserved and Rural Communities.

Authors:  Robert D Annett; Sheva Chervinskiy; Thomas H Chun; Kelly Cowan; Kristina Foster; Nathaniel Goodrich; Matthew Hirschfeld; Daniel S Hsia; J Dean Jarvis; Kurtis Kulbeth; Christi Madden; Clare Nesmith; Hengameh Raissy; Judith Ross; J Philip Saul; Bruce Shiramizu; Paul Smith; Janice E Sullivan; Lauren Tucker; Andrew M Atz
Journal:  Pediatrics       Date:  2020-09-17       Impact factor: 7.124

4.  Association between neonatal intensive care unit medication safety practices, adverse events, and death.

Authors:  Laura E Miller; Chris DeRienzo; P Brian Smith; Carl Bose; Reese H Clark; C Michael Cotten; Daniel K Benjamin; Chi D Hornik; Rachel G Greenberg
Journal:  J Perinatol       Date:  2020-10-08       Impact factor: 2.521

5.  Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records.

Authors:  Christoph P Hornik; Andrew M Atz; Catherine Bendel; Francis Chan; Kevin Downes; Robert Grundmeier; Ben Fogel; Debbie Gipson; Matthew Laughon; Michael Miller; Michael Smith; Chad Livingston; Cindy Kluchar; Anne Heath; Chanda Jarrett; Brian McKerlie; Hetalkumar Patel; Christina Hunter
Journal:  Appl Clin Inform       Date:  2019-05-08       Impact factor: 2.342

6.  An Innovative Approach to Building an Effective and Efficient Pediatric Trial Network.

Authors:  Rachel L Randell; Daniel K Benjamin; Rachel G Greenberg
Journal:  Hosp Pediatr       Date:  2022-09-01

7.  Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections.

Authors:  Jessica E Ericson; Martyn Gostelow; Julie Autmizguine; Christoph P Hornik; Reese H Clark; Daniel K Benjamin; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2017-04       Impact factor: 3.806

8.  Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants.

Authors:  Sara Salerno; Christoph P Hornik; Michael Cohen-Wolkowiez; P Brian Smith; Lawrence C Ku; Matthew S Kelly; Reese Clark; Daniel Gonzalez
Journal:  Pediatr Infect Dis J       Date:  2017-09       Impact factor: 3.806

9.  Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants.

Authors:  Christoph P Hornik; Nikolas J Onufrak; P Brian Smith; Michael Cohen-Wolkowiez; Matthew M Laughon; Reese H Clark; Daniel Gonzalez
Journal:  Cardiol Young       Date:  2017-08-08       Impact factor: 1.023

10.  Capacity Building in a New Clinical Trials Network through Inter-Network Collaboration.

Authors:  Lisa Knight; Barbara A Pahud; Margaret Scheffler; Joshua C Euteneuer; Christine Allen; Judith Ross; Wail Ali; Marisa Meyer; Prashant J Purohit; Kanecia O Zimmerman; Janice E Sullivan
Journal:  J Pediatr       Date:  2021-04-30       Impact factor: 6.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.